Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | BLM | P54132 | 3/20 | 0.75 |
| ▸ | USP2 | O75604 | 3/20 | 0.75 |
| ▸ | TP53 | P04637 | 3/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.75 |
| ▸ | RECQL | P46063 | 3/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.75 |
| ▸ | NSD2 | O96028 | 3/20 | 0.75 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.75 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.75 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.75 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | TOP2A | P11388 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | MTOR | P42345 | 2/20 | 0.75 |
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326995 | 0.93 | MEN1 (0.66) | MEN1KMT2ABLMUSP2TP53 | |
| SCHEMBL10524500 | 0.90 | CYP19A1 (0.73) | MEN1KMT2ABLMUSP2TP53 | |
| SCHEMBL4885984 | 0.90 | CYP19A1 (0.68) | MEN1KMT2ABLMUSP2TP53 | |
| SCHEMBL11517791 | 0.90 | CYP19A1 (0.68) | MEN1KMT2ABLMUSP2TP53 | |
| SCHEMBL29350310 | 0.90 | CYP19A1 (0.68) | MEN1KMT2ABLMUSP2TP53 | |
| SCHEMBL12282411 | 0.90 | MEN1 (0.66) | MEN1KMT2ABLMUSP2TP53 | |
| Hydrochloric Acid SCHEMBL11150067 | 0.89 | CYP19A1 (0.71) | MEN1KMT2ABLMUSP2TP53 | |
| SCHEMBL11279729 | 0.89 | CYP19A1 (0.71) | MEN1KMT2ABLMUSP2TP53 | |
| Hydrochloric Acid SCHEMBL7204221 | 0.89 | CYP19A1 (0.66) | MEN1KMT2ABLMUSP2TP53 | |
| SCHEMBL13993010 | 0.88 | KMT2A (0.63) | MEN1KMT2ABLMUSP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4456552-A | CHELATION, ANTITUMOR | AMERICAN CYANAMID COMPANY (US) | 1984-06-26 | — | — | US | claimed |
| US-20170071950-A1 | METHODS FOR INHIBITING CELLULAR UPTAKE OF THE ANTHRAX LETHAL TOXIN (LT) PROTEIN COMPLEX | ENZO BIOCHEM, INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-8969339-B2 | Compositions and methods for bone formation and modeling | ENZO BIOCHEM, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969339-B2 | Compositions and methods for bone formation and modeling | ENZO BIOCHEM, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130172332-A1 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING | ENZO BIOCHEM, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172332-A1 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING | ENZO BIOCHEM, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8367822-B2 | Compositions and methods for bone formation and remodeling | ENZO THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367822-B2 | Compositions and methods for bone formation and remodeling | ENZO THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2009035430-A2 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND REMODELING | ENZO THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-4820738-A | ANTITUMOR AGENTS; CHELATING AGENTS; GROWTH INHIBITORS; LEUKEMIA | AMERICAN CYANAMID COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| US-4614618-A | CHELATING AGENTS AND ANTICANCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-09-30 | — | — | US | disclosed |
| US-4540519-A | CHELATE COMPOUNDS, ANTICANCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1985-09-10 | — | — | US | disclosed |
| US-4526989-A | And ascorbic acid salt | AMERICAN CYANAMID COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| US-4456552-A | CHELATION, ANTITUMOR | AMERICAN CYANAMID COMPANY (US) | 1984-06-26 | — | — | US | disclosed |
| US-4430501-A | CHELATION, ANTITUMOR, COMPLEXING, SEQUESTERING | AMERICAN CYANAMID COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
| EP-0037486-B1 | METAL CHELATES OF 1,4-BIS(SUBSTITUTED-AMINO)-5,8-DIHYDROXY-ANTHRAQUINONES | AMERICAN CYANAMID COMPANY (US) | 1984-01-25 | — | — | EP | disclosed |
| US-4296030-A | ANTITUMOR AGENTS, DYES | AMERICAN CYANAMID COMPANY (US) | 1981-10-20 | — | — | US | disclosed |
| EP-0037486-A2 | Metal chelates of 1,4-bis(substituted-amino)-5,8-dihydroxy-anthraquinones | AMERICAN CYANAMID COMPANY (US) | 1981-10-14 | — | — | EP | disclosed |
| US-4278689-A | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-07-14 | — | — | US | disclosed |
| US-4197249-A | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172332-A1 | COMPOSITIONS AND METHODS FOR BONE FORMATION AND MODELING | LRP6, BMP6, WNT3A | MEN1 3827/4885KMT2A 4661/4885BLM 4476/4885 |
| US-20170071950-A1 | METHODS FOR INHIBITING CELLULAR UPTAKE OF THE ANTHRAX LETHAL TOXIN (LT) PROTEIN COMPLEX | ANTXR2, LRP6, WNT3A | MEN1 3828/4885KMT2A 4689/4885BLM 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.